Professor of medicine, Deputy director, UPMC Hillman Cancer Center; Assistant vice chancellor for community health equity, Health Sciences, University of Pittsburgh School of Medicine
Professor, Department of Social Science and Public Health Policy, Associate director, Community Outreach and Engagement, Atrium Health/Wake Forest Comprehensive Cancer Center/Levine Cancer Institute
Associate professor of epidemiology & biostatistics, University of California San Francisco; Director, Office of Community Engagement, Associate Director for Community Outreach and Engagement, UCSF Helen Diller Family Comprehensive Cancer Center
Associate center director, Community Outreach & Engagement, Director, Center for Health Equity & Community Knowledge in Urban Populations, Faculty supervisor, Office of Cancer Health Equity & Community Engagement, Karmanos Cancer Institute, Professor, Department of Oncology, Wayne State University School of Medicine
Professor, Department of Population Sciences, Beckman Research Institute of City of Hope; Deputy director, Division of Health Equities, Associate cancer center director, Community Outreach and Engagement, Founding director, Center of Community Alliance for Research & Education, City of Hope
Enterprise deputy director, Community Outreach and Engagement, Cancer Prevention, Survivorship & Care Delivery, Mayo Clinic Comprehensive Cancer Center
Interim founding dean, School of Population Health, Virginia Commonwealth University, Associate director, Community Outreach Engagement and Health Disparities Research, VCU Massey Comprehensive Cancer Center
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.
Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
The University of Rochester Wilmot Cancer Institute last week was named the 73rd NCI-designated cancer center. Now, New York State has eight NCI-designated cancer centers. Only California has more—ten.
The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.